We confirm here that microinjection of KRASG12D [71] mRNA, a tumor-inducing KRAS mutant, results in the formation of the ITLSs that we have previously shown to exhibit classic hallmarks of tumors, including histopathology, increased proliferation, lack of differentiation, attraction of vasculature, etc. [3, 4, 41]. The gene discussed is KRAS; the disease is neoplasm.